ASX Announcements
Change in substantial holding, Security holder details - Other
- Nov 4, 2024
- 479 pages
FPH to announce half year results on 28 November 2024
Notification of Results/Reporting Date, Web Casts
- Oct 23, 2024
- 1 page
Application for quotation of securities - FPH
Appendix 2A (Application for Quotation of Securities)
- Oct 2, 2024
- 8 pages
August
Fisher & Paykel ups earnings guidance as hospital rates rise
The New Zealand company says margin improvements and growing demand for its products from hospitals is driving earnings.
- Michael Smith
May
Fisher & Paykel leaves pandemic behind as respirator demand grows
Earlier this year, Vertium Asset Management’s Jason Teh put the New Zealand-based group on his list of turnaround prospects. Issues at its rival are helping.
- Kylar Loussikian
February
This fundie says Domino’s Pizza is a better bet than the big four
Vertium Asset Management’s Jason Teh has an eye for companies in a turnaround phase – and his gaze is now firmly set on Domino’s and Fisher & Paykel Healthcare.
- Joanne Tran
May 2023
Fisher & Paykel net profit slumps 34pc
Shares in respirator company Fisher & Paykel dived 6.3 per cent to $22.48 after its disappointing earnings result.
- Elouise Fowler
November 2022
These 10 shares would have made you 888pc-plus in a decade
A standout lesson from the top performers over the last 10 years is that investors who ignore Australian IT companies do so at their peril.
- Jennifer Mead
November 2021
Fisher & Paykel shares rise on strong first-half results
The company’s latest six month numbers sales and profits fell slightly against a record last year amid surging COVID-19 hospitalisations.
- Updated
- Carrie LaFrenz
June 2021
Perfect economic conditions for healthcare to thrive
A survey of sophisticated and wholesale investors by Citi found 46 per cent believe healthcare is the sector of the economy that shows most promise.
- Aleks Vickovich
May 2021
Fisher & Paykel Healthcare posts record result as profit surges 82pc
But the dual-listed company’s margins were crunched by the doubling of freight costs.
- Carrie LaFrenz
The ‘sleep at night’ fund that still delivers the goods
Sage Capital’s Kelli Meagher believes there are permanent winners from COVID-19 – it just means being selective and having an instinct for identifying change.
- Vesna Poljak
January 2021
ASX up 1.3pc in huge week for Zip, Lynas
The Australian sharemarket fell 0.3 per cent on Friday but ended the week higher on US stimulus hopes. Lynas surged 13.7 per cent on Friday after inking a deal with the Pentagon.
- Updated
- Robert Guy, Vesna Poljak, Sarah Turner, Luke Housego and Tom Richardson
Healthcare outlook rests on vaccine rollout
Many healthcare companies were seriously disrupted while dealing with the fallout from COVID-19. As vaccines get rolled out, momentum is likely to return.
- Carrie LaFrenz
November 2020
ASX gains 0.6pc, rallies to nine-month high
The Australian sharemarket has come within one point of recouping its losses for the year as banks and miners gained after Wall St closed at a record high. Tech stocks tumbled as funds rotated into value stocks.
- Updated
- Robert Guy, Sarah Turner, William McInnes, Luke Housego and Tom Richardson
- Opinion
- Chanticleer
The ASX health giant riding COVID’s second wave
Fisher & Paykel Healthcare's humidifiers have become vital to the treatment of COVID-19 cases. But investors are starting to look beyond the virus.
- Updated
- James Thomson
Fisher & Paykel Healthcare posts record profit on COVID-19 demand
The $18.6 billion dual-listed company beat analysts' expectations for the half year, while upgrading its full-year outlook.
- Carrie LaFrenz
ASX falls; Sohn conference tips CSL, Treasury Wines, Temple & Webster
The sharemarket closed 0.2 per cent lower on Friday. Sohn Hearts & Mind saw Paradice's David Moberley spy 'significant' opportunity in CSL. Regal said Temple & Webster can double and Tribeca was bullish on Treasury Wine. Milford liked Fisher & Paykel Healthcare.
- Updated
- Robert Guy, Vesna Poljak, Sarah Turner, William McInnes, Luke Housego and Tom Richardson
- Exclusive
- Coronavirus pandemic
Vaccine will be a panacea for Ramsay, CSL and ResMed
John Deakin-Bell expects at least one of the leading drug candidates will be successful, helping healthcare earnings return to "normal" by next financial year.
- Carrie LaFrenz
October 2020
Buy, hold, sell: Afterpay, ANZ, Transurban, Woodside Petroleum, CSL
Two fund managers look at the stocks that you can afford to buy on a 10-year view.
September 2020
- Analysis
- Sharemarket
How a Trump or Biden win will affect shareholders
Tax and healthcare are two key areas where the ASX is exposed to the US election. But the broader implications extend far beyond.
- Luke Housego
August 2020
ResMed longer-term growth fundamentals 'still intact'
Chief executive Mick Farrell is tipping a U-shaped recovery out of COVID-19 for the dual-listed medical device and software company.
- Carrie LaFrenz
July 2020
Buy, hold, sell: Newcrest Mining, Telstra, Zip Co, CSL, Domain
Fund managers from Tribeca and Firetrail pick the stocks they like - and the ones they don't.